

ForPatients

by Roche

Mild to severe ulcerative colitis

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Trial Status
Recruiting

Trial Runs In
4 Countries

Trial Identifier
NCT07158242 2025-522518-22-00
CA45905

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT07158242 2025-522518-22-00 CA45905
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=2 Years & <= 17 Years

Healthy Volunteers
No
